Mesoblast (MESO) Net Income towards Common Stockholders (QoQ) (2014 - 2023)

Mesoblast (MESO) Net Income towards Common Stockholders (QoQ) (2014 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Mesoblast 18.89 Bn 18.76 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2023 -17.84%
Mar 31, 2023 24.04%
Dec 31, 2022 -45.02%
Sep 30, 2022 21.31%
Jun 30, 2022 -0.72%
Mar 31, 2022 17.90%
Dec 31, 2021 -14.57%
Sep 30, 2021 -2.65%
Jun 30, 2021 16.80%
Mar 31, 2021 -3.20%
Dec 31, 2020 -4.68%
Sep 30, 2020 24.73%
Jun 30, 2020 -113.65%
Mar 31, 2020 37.91%
Dec 31, 2019 -348.29%
Sep 30, 2019 73.54%
Jun 30, 2019 17.00%
Mar 31, 2019 -1.49%
Dec 31, 2018 -26.19%
Sep 30, 2018 6.41%